PCN82 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN THE ITALIAN SETTING.

Authors :: Di Rienzo, P.
Mennini, F.S.
Marcellusi, A.
Bini, C.
Augusto, M.
Orsini, I.
Teitsson, S.
Amadi, A.
Source :: Value in Health. 2019 Supplement 3, Vol. 22, pS451-S452. 2p.
Publication Year :: 2019
Abstract: The purpose of this analysis was to evaluate the cost-effectiveness of nivolumab as an adjuvant treatment for adults suffering from melanoma with involvement of lymph nodes or metastatic disease, after having undergone complete resection from the Italian healthcare system. Overall survival (OS) was modelled using an RFS/ OS correlation equation supported by published literature. [Extracted from the article]

Full Text Access

Tools